If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
By the end of the year, there were 12,000 Cuban soldiers inside Angola, nearly the size of the entire SADF presence in South West Africa. The FNLA suffered a crushing defeat at the Battle of Quifangondo when it attempted to take Luanda on 10 November, and the capital remained in FAPLA hands by independence.
mistranslation The insertion of an incorrect amino acid in a growing peptide chain during translation, i.e. the inclusion of any amino acid that is not the one specified by a particular codon in an mRNA transcript. Mistranslation may originate from a mischarged transfer RNA or from a malfunctioning ribosome.
Per- and Polyfluoroalkyl Substances (PFAS) at the National Toxicology Program Per- and Polyfluoroalkyl Substances and Your Health at the Agency for Toxic Substances and Disease Registry Per- and Polyfluoroalkyl Substances (PFAS) at the EPA Per- and polyfluoroalkyl substances (PFASs) at the European Chemicals Agency PFAS contamination map of Europe Per- and Polyfluoroalkyl substances, National Institute for Occupational Safety and Health The Forever Pollution Project – Journalists tracking PFAS across Europe PFAS contamination in Queensland, Australia, State Library of Queensland "Contaminated: The Carpet Industry's Toxic Legacy". Frontline. Season 44. Episode 8. 3 February 2026. PBS. WGBH. Retrieved 25 February 2026.
=== 5 May === In Berdiansk, Yevgeniy Ananievsky, a Russian-appointed official allegedly responsible for setting up torture chambers in occupied Zaporizhzhia Oblast, was killed after a bomb exploded in his car. Two people were killed by Russian rockets in Pokrovsk. One person was killed by Russian shelling in Kharkiv Oblast. The Sloviansk Thermal Power Plant in Donetsk Oblast was also damaged by Russian shelling. Ukrainian former Olympic weightlifter turned soldier Oleksandr Pielieshenko was killed in action.
Caldwell Dyson was assigned for her second space flight on November 21, 2008. Her second space mission consisted of a six-month trip to the International Space Station. Caldwell Dyson successfully lifted off on April 2, 2010, from the Baikonur spaceport on board the Soyuz TMA-18 as Flight Engineer 2 with Soyuz Commander Aleksandr Skvortsov and Flight Engineer 1 Mikhail Korniyenko. Following a two-day rendezvous and docking maneuver with the ISS, she joined Expedition 23 as a flight engineer and transferred on June 2, 2010, to Expedition 24 again as a flight engineer after the departure of the Soyuz TMA-17. During the first half of her flight, Caldwell Dyson and the Expedition 23 crew were joined by the STS-131 crew from April 7 to April 17. This period was the first and only time that four women were together on board the same spacecraft: Caldwell Dyson, NASA astronauts Stephanie Wilson and Dorothy Metcalf-Lindenburger, and JAXA astronaut Naoko Yamazaki. From May 16 to May 23, the second and last Space Shuttle visiting mission for Caldwell-Dyson's flight, STS-132, joined the Expedition 23 crew for the installation of the Russian-built module Rassvet. The second half of Caldwell Dyson's mission was marked by the failure of a coolant pump at the beginning of August. Caldwell Dyson performed her first spacewalk on August 7, 2010, with NASA astronaut Douglas Wheelock. The task for this first of three contingency EVAs was to prepare the malfunctioning coolant pump for replacement on the next spacewalks; this took place on August 11, 2010, and August 16, 2010.
Sources: en.wikipedia.org
=== Further medieval development === The Fisher King's next development occurred around the end of the 12th century in Robert de Boron's Joseph d'Arimathie, the first work to connect the Grail with Jesus. Here, the "Rich Fisher" is called Bron, a name similar enough to Bran to suggest a relationship, and said to be the brother-in-law of Joseph of Arimathea, who had used the Grail to catch Christ's blood before laying him in the sepulchre. Joseph founds a religious community that travels eventually to Britain and entrusts the Grail to Bron (who is called the "Rich Fisher" because he catches a fish eaten at the Grail table). Bron founds the line of Grail keepers that eventually includes Perceval. The Lancelot-Grail (Vulgate) prose cycle includes a more elaborate history of the Fisher King. Many in his line are wounded for their failings, beginning with his ancestor Alain (the "Rich Fisherman"), and the only two that survived till the Grail Quest are the Maimed King, named Pellehan (Pellean, Pelleam, Pellehem), and the Fisher King, his son Pelles. The Vulgate Merlin Continuation further features besides his father, unnamed there, a brother of Pelles also named Alain, and in one variant also their brother and their cousin both named Pellinor, all featuring as Grail Kings of the Fisher and/or Maimed kind. Pelles engineers the birth of Galahad by tricking Lancelot into bed with his daughter Elaine, and it is prophesied that Galahad will achieve the Grail and heal the Wasteland and the Maimed King.
The government announces that TikTok is to be banned on electronic devices used by ministers and other employees, amid security concerns relating to the Chinese-owned app's handling of user data. Scientists identify a gene variant that is known to increases the risk of breast and ovarian cancer, and trace it to people with Orkney Island heritage, more specifically those with ancestry on the island of Westray. COVID-19 in the UK: Office for National Statistics data for the week ending 7 March (6 March in Scotland) indicates COVID-19 cases are falling in Scotland, but the picture is uncertain in the rest of the UK. In England, the survey suggests that 1,322,000 tested positive for the virus, equating to 2.36% of the population, or around 1 in 40. 18 March – Peter Murrell resigns as CEO of the Scottish National Party amid a row over party membership. 19 March The UK government launches the Emergency Alerts service, a service to send text alerts to mobile phones in a situation where it is perceived there is an immediate risk to life. The BBC urges its staff to delete the TikTok app from its official devices amid concerns about its security. 20 March – The British government bans far-right Danish activist Rasmus Paludan from entering the United Kingdom over a threat to burn a Quran in Wakefield, West Yorkshire. 21 March Partygate scandal: Former prime minister Boris Johnson publishes a 52-page defence of his actions during the COVID-19 pandemic in which he acknowledges misleading Parliament over the Partygate scandal, but says he did not do so intentionally.
Generally, gold nanoparticles are produced in a liquid ("liquid chemical methods") by reduction of chloroauric acid (H[AuCl4]). To prevent the particles from aggregating, stabilizing agents are added. Citrate acts both as the reducing agent and colloidal stabilizer. They can be functionalized with various organic ligands to create organic-inorganic hybrids with advanced functionality.
== See also == Butyric acid α-Aminobutyric acid (homoalanine) 2-Hydroxybutyric acid (α-hydroxybutyric acid) Other oxobutanoic acids 3-Oxobutanoic acid (acetoacetic acid) 4-Oxobutanoic acid (succinic semialdehyde)
== External links == "Richardson Laboratory website". "MolProbity structure validation website". "Jane and David Richardson Papers, Duke University Medical Center Archives". "Jane S. Richardson Oral History Interview, Duke University Medical Center Archives".
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.